×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
戻る Agenda
Session 25: Regulatory Compliance and FDA Inspections: What To Expect After Submitting the NDA
Session Chair(s)
Elliott Berger, PhD, MS
President
ETB Regualtory Consulting, United States
- GLP inspections
- GCP inspections
- Inspection outcomes: additional considerations in GCP inspections
- GMP inspections
- Inspection outcomes (GLPs, GCPs, GMPs)
- FDA enforcement actions
- Application Integrity Policy (AIP)